Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin + Gemcitabine in Advanced Liposarcoma or Leiomyosarcoma
NCT03810976Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Mar 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin in Liposarcoma and leiomyosarcoma (LMS), sponsored by Yonsei University. Primary endpoint: Progression-Free Survival Rate at 12 weeks. Started Mar 2018; status: completed.
02
Drugs
eribulin
03
Conditions
Liposarcomaleiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT03810976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03810976.